About
We believe that a significant change is ongoing in the way patients with cancer are followed: practices are now moving from a general medicine that is "tumor-centric" to a personalized medicine that also considers the "patient" ability to fight against the tumor. To make this change happen, industrials need to offer new solutions in Immuno-diagnostics and therapeutics. In immuno-diagnostics, OncoStance is the first company developing tests that can measure the intensity of the immune response in patients who underwent cancer surgery. By using OncoStance patient-centric tests in addition to the usual tumor-centric prognostic tests, oncologists will be able to better predict the disease evolution and to take a more suited therapeutic decision for each patient.